



## Alice C. Fan

Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center  
Medicine - Oncology

### CLINICAL OFFICES

- **Medical Oncology**

875 Blake Wilbur Dr

MC 6560

Stanford, CA 94305

**Tel** (650) 498-6000

**Fax** (650) 724-1231

### Bio

---

### CLINICAL FOCUS

- Cancer > Urologic Oncology
- Urologic Neoplasms
- Kidney Cancer
- Translational Medical Research
- Molecular Targeted Therapy
- Nano-proteomics
- Clinical Trials as Topic
- Medical Oncology

### ACADEMIC APPOINTMENTS

- Assistant Professor - Med Center Line, Medicine - Oncology
- Member, Bio-X
- Member, Stanford Cancer Institute
- Faculty Fellow, Stanford ChEM-H

### ADMINISTRATIVE APPOINTMENTS

- Research Mentor, Canary Cancer Research Education Summer Training (CREST) Program, (2019- present)
- Member, Stanford BioX Program, (2016- present)
- Faculty Fellow, ChemH [Chemistry, Engineering & Medicine for Human Health Institute], (2018- present)
- Faculty Member, Cancer Center at Stanford for Early Cancer Detection, (2017- present)
- Member, Stanford Kidney Cancer Research Group, (2011- present)
- Interviewer, Stanford School of Medicine Internal Medicine Residency, (2011- present)

- Research Mentor, NIH/NIDDK Short term education program for under-represented persons, (2011-2011)
- Clinical Mentor, Stanford Molecular Imaging Scholars Program, (2010- present)
- Associate Member, Stanford Cancer Institute Translational Oncology Program, (2008- present)
- Founding Advisor, Stanford Association for Multidisciplinary Medicine and Science, (2008-2013)
- Member, Stanford Lymphoma Disease Management Group, (2005-2013)

## HONORS AND AWARDS

- Career Development Award, ConquerCancer/ASCO (2016-2019)
- K23 Career Development Award, NIH/NCI (July 2010-June 2015)
- R21: Analysis of CTCs for Early Prediction of Response to Treatment in RCC, NIH/NCI (2014-2016)
- Innovation Award, Stanford Cancer Institute (2014-2016)
- Center for Cancer Nanotechnology Excellence: leader of the Clinical Translational Core, NIH/NCI (2015-2020)
- R21: Nanoscale proteomic profiles of hypoxia pathways to develop biomarkers of renal cell carcinoma, NIH/NCI (August 2012-July 2014)
- Developmental Cancer Research Award, Stanford Cancer Institute (September 2011-August 2012)
- TRAM Renewal Grant: Development of blood biomarkers for diagnosis and monitoring of kidney cancer, Stanford Department of Medicine (October 2012-August 2013)
- Translational Research and Applied Medicine Program (TRAM) Pilot Grant, Stanford Department of Medicine (October 2011-September 2012)
- Special Fellow in Clinical Research, Leukemia and Lymphoma Society (July 2006-June 2009)
- Research Fellowship, Lymphoma Research Foundation (July 2004-June 2006)
- Dean's Fellowship, Stanford School of Medicine (April 2004- March 2005)

## PROFESSIONAL EDUCATION

- Fellowship: Stanford University Hematology and Oncology Fellowship (2006) CA
- Medical Education: Albany Medical College Office of the Registrar (1998) NY
- Board Certification: Medical Oncology, American Board of Internal Medicine (2004)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2001)
- Residency: Warren Alpert Medical School Brown University (2001) RI
- Internship: Warren Alpert Medical School Brown University (1999) RI
- B.A., Harvard College , Biophysics (1994)

## COMMUNITY AND INTERNATIONAL WORK

- Student Travel Health, Stanford Orchestra Tour Physician, Australia, New Zealand, China
- Violinist, Stanford Hospital Bing Music Series, Stanford Hospital
- Founding member of non-profit organization, "Lemonaide", Stanford Cancer Center
- Outreach Speaker, Chinese Community Clinical Trials Forum
- Grand Rounds Speaker, Hualien Hospital serving aboriginal and local Taiwanese populations, Taiwan

## PATENTS

- Alice Fan, Dean Felsher. "United States Patent 10145851 Discovery and validation of cancer biomarkers using a protein analysis methodology to analyze specimens", Leland Stanford Junior University, Dec 4, 2018

## LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

## Research & Scholarship

---

### CURRENT RESEARCH AND SCHOLARLY INTERESTS

Dr. Fan studies how turning off oncogenes (cancer genes) can cause tumor regression in preclinical and clinical studies. Based on preclinical findings, she has initiated clinical trials studying how tyrosine kinase inhibitors impact the hypoxia pathway in kidney cancer and the use of atorvastatin for the treatment of patients with certain non-Hodgkin's lymphomas. In the laboratory, she also uses preclinical models of cancer to validate new nanotechnology strategies for tumor diagnosis and treatment. She has shown that a new nano-immunoassay (NIA) can be used to measure how well drugs work in tumor cells sampled from individual patients with leukemia, lymphoma and myelodysplastic syndrome taking novel targeted therapies (Fan et al. Nature Medicine 2009, Seetharam, Fan et al. Leukemia Research 2012, Fan et al Oncotarget 2012). She is currently expanding her translational research to include early diagnostics, therapeutic monitoring, and prediction of response to therapeutics in solid tumors such as kidney cancer and lung cancer, with the goal of helping to make personalized medicine possible.

### CLINICAL TRIALS

- S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer, Recruiting
- Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors, Recruiting
- Study CB-839 in Combination With Nivolumab in Patients With Melanoma, ccRCC and NSCLC, Recruiting
- 18F-FSPG PET/CT for Cancer Patients on Therapy, Not Recruiting
- A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC), Not Recruiting
- A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer, Not Recruiting
- A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2), Not Recruiting
- A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection, Not Recruiting
- A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4, Not Recruiting
- Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients, Not Recruiting
- An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer, Not Recruiting
- An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy, Not Recruiting
- CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma, Not Recruiting
- ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC, Not Recruiting
- Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer, Not Recruiting
- Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma, Not Recruiting
- Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214), Not Recruiting
- ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer, Not Recruiting
- Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma, Not Recruiting
- Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma, Not Recruiting
- Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts, Not Recruiting
- Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors, Not Recruiting
- Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers, Not Recruiting
- Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma, Not Recruiting
- Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer, Not Recruiting

- Study of the Glutaminase Inhibitor CB-839 in Solid Tumors, Not Recruiting

## Teaching

---

### GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Medicine (Masters Program)

## Publications

---

### PUBLICATIONS

- **A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-Deficient Renal Cell Carcinoma in 32 Patients.** *The American journal of surgical pathology*  
Lau, H. D., Chan, E., Fan, A. C., Kunder, C. A., Williamson, S. R., Zhou, M., Idrees, M. T., Maclean, F. M., Gill, A. J., Kao, C.  
2019
- **Postmarketing Analysis of Sipuleucel-T-The Importance of Real-World Data.** *JAMA network open*  
Fan, A. C., Leppert, J. T.  
2019; 2 (8): e199233
- **F-18-FPPRGD(2) PET/CT in patients with metastatic renal cell cancer** *EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING*  
Torihara, A., Duan, H., Thompson, H. M., Park, S., Hatami, N., Baratto, L., Fan, A. C., Iagaru, A.  
2019; 46 (7): 1518–23
- **Early Changes in CT Perfusion Parameters: Primary Renal Carcinoma Versus Metastases After Treatment with Targeted Therapy** *CANCERS*  
Fan, A. C., Sundaram, V., Kino, A., Schmiedeskamp, H., Metzner, T. J., Kamaya, A.  
2019; 11 (5)
- **18F-FPPRGD2 PET/CT in patients with metastatic renal cell cancer.** *European journal of nuclear medicine and molecular imaging*  
Torihara, A., Duan, H., Thompson, H. M., Park, S., Hatami, N., Baratto, L., Fan, A. C., Iagaru, A.  
2019
- **The 'Achilles Heel' of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy.** *Kidney cancer*  
Hoerner, C. R., Chen, V. J., Fan, A. C.  
2019; 3 (1): 15–29
- **Early Changes in CT Perfusion Parameters: Primary Renal Carcinoma Versus Metastases After Treatment with Targeted Therapy.** *Cancers*  
Fan, A. C., Sundaram, V., Kino, A., Schmiedeskamp, H., Metzner, T. J., Kamaya, A.  
2019; 11 (5)
- **Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma.** *Cancers*  
Chen, V. J., Hernandez-Meza, G., Agrawal, P., Zhang, C. A., Xie, L., Gong, C. L., Hoerner, C. R., Srinivas, S., Oermann, E. K., Fan, A. C.  
2019; 11 (7)
- **Multiregion Quantification of Extracellular Signal-regulated Kinase Activity in Renal Cell Carcinoma.** *European urology oncology*  
Hoerner, C. R., Massoudi, R., Metzner, T. J., Stell, L., O'Rourke, J. J., Kong, C. S., Liliental, J. E., Brooks, J. D., Sabatti, C., Leppert, J. T., Fan, A. C.  
2018
- **Serum miR371a Quantitation for Assessing Tumor Burden in Testicular Germ Cell Tumors**  
Kunder, C., Imae, Y., Srinivas, S., Fan, A. C.  
NATURE PUBLISHING GROUP.2018: 703
- **Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC).**  
Tannir, N. M., Fan, A. C., Lee, R. J., Carthon, B., Iliopoulos, O., Mier, J., Patel, M. R., Meric-Bernstam, F., DeMichele, A., Voss, M., Harding, J. J., Srinivasan, R., Shapiro, et al  
AMER SOC CLINICAL ONCOLOGY.2018
- **A phase 1/2 study of CB-839, a first-in-class glutaminase inhibitor, combined with nivolumab in patients with advanced melanoma (MEL), renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC)**

- Meric-Bernstam, F., Gordon, M., Tykodi, S., Lam, E., Vaishampayan, U., Chaves, J., Nikolinakos, P., Fan, A., Lee, R., McDermott, D., Shapiro, G., Gandhi, L., Tawbi, et al  
BMC.2017
- **Consolidative Radiotherapy in Metastatic Urothelial Cancer.** *Clinical genitourinary cancer*  
Shah, S., Zhang, C. A., Hancock, S., Fan, A., Skinner, E., Srinivas, S.  
2017
  - **Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.** *Expert opinion on investigational drugs*  
Fan, A. C., O'Rourke, J. J., Praharaj, D. R., Felsher, D. W.  
2013; 22 (11): 1495-1509
  - **Use of nano-immuno assay to generate rapid, quantitative nanoscale proteomic profiling of the hypoxia pathway in renal cell carcinoma clinical specimens.**  
Fan, A. C., Banerjee, P., Leppert, J., Harshman, L., Sabatti, C., Brooks, J. D., Felsher, D. W.  
AMER SOC CLINICAL ONCOLOGY.2012
  - **Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens** *NATURE MEDICINE*  
Fan, A. C., Deb-Basu, D., Orban, M. W., Gotlib, J. R., Natkunam, Y., O'Neill, R., Padua, R., Xu, L., Taketa, D., Shirer, A. E., Beer, S., Yee, A. X., Voehringer, et al  
2009; 15 (5): 566-571
  - **Supramolecular Stacking of Doxorubicin on Carbon Nanotubes for In Vivo Cancer Therapy** *ANGEWANDTE CHEMIE-INTERNATIONAL EDITION*  
Liu, Z., Fan, A. C., Rakhra, K., Sherlock, S., Goodwin, A., Chen, X., Yang, Q., Felsher, D. W., Dai, H.  
2009; 48 (41): 7668-7672
  - **A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice** *MOLECULAR CANCER*  
Fan, A. C., Goldrick, M. M., Ho, J., Liang, Y., Bachireddy, P., Felsher, D. W.  
2008; 7
  - **Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas** *PLOS ONE*  
Tran, P. T., Fan, A. C., Bendapudi, P. K., Koh, S., Komatsubara, K., Chen, J., Horng, G., Bellovin, D. I., Giuriato, S., Wang, C. S., Whitsett, J. A., Felsher, D. W.  
2008; 3 (5)
  - **F-18-FPPRGD(2) PET/CT in patients with metastatic renal cell cancer**  
Torihara, A., Duan, H., Park, S., Hatami, N., Baratto, L., Fan, A., Iagaru, A.  
SOC NUCLEAR MEDICINE INC.2018
  - **Clinicopathologic Characteristics of Fumarate Hydratase-Deficient and Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Series of 10 Cases**  
Lau, H., Williamson, S. R., Kunder, C., Fan, A. C., Kao, C.  
NATURE PUBLISHING GROUP.2018: 358
  - **Clinicopathologic Characteristics of Fumarate Hydratase-Deficient and Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Series of 10 Cases**  
Lau, H., Williamson, S. R., Kunder, C., Fan, A. C., Kao, C.  
NATURE PUBLISHING GROUP.2018: 358
  - **Serum miR371a Quantitation for Assessing Tumor Burden in Testicular Germ Cell Tumors**  
Kunder, C., Imae, Y., Srinivas, S., Fan, A. C.  
NATURE PUBLISHING GROUP.2018: 703
  - **Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations** *JCO PRECISION ONCOLOGY*  
Carneiro, B. A., Collier, K., Nagy, R. J., Pamarthy, S., Sagar, V., Fairclough, S., Odegaard, J., Lanman, R. B., Costa, R., Taxter, T., Kuzel, T. M., Fan, A., Chae, et al  
2018; 2
  - **KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study (vol 50, pg 123, 2016)** *LEUKEMIA RESEARCH*

- Swords, R. T., Greenberg, P. L., Wei, A. H., Durrant, S., Advani, A. S., Hertzberg, M. S., Lewis, I. D., Rivera, G., Gratzinger, D., Fan, A. C., Felsher, D. W., Cortes, J. E., Watts, et al  
2017; 59: 65
- **Economic burden of empiric drug utilization in metastatic renal cell carcinoma emphasizes the need for early biomarkers of response.**  
Chen, V., Gong, C., Zhang, C. A., Srinivas, S., Lee, H. E., Fan, A. C.  
AMER SOC CLINICAL ONCOLOGY.2017
  - **Pilot study of F-18-FSPG vs F-18-FDG PET imaging for response assessment in cancer**  
Park, S., Hatami, N., Rutledge, O., Koglin, N., Loo, B., Fan, A., Mittra, E.  
SOC NUCLEAR MEDICINE INC.2017
  - **INTRA-TUMOR HETEROGENEITY IN RENAL CELL CARCINOMA: IMPLICATIONS FOR PROTEOMIC ANALYSIS OF RENAL MASS BIOPSIES**  
Massoudi, R., Hoerner, C., Metzner, T., O'Rourke, J., Curtis, R., Stell, L., Sabatti, C., Brooks, J., Fan, A., Leppert, J.  
ELSEVIER SCIENCE INC.2017: E496–E497
  - **High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.** *Science translational medicine*  
Sharma, A., Burrige, P. W., McKeithan, W. L., Serrano, R., Shukla, P., Sayed, N., Churko, J. M., Kitani, T., Wu, H., Holmström, A., Matsa, E., Zhang, Y., Kumar, et al  
2017; 9 (377)
  - **Monitoring Neutropenia for Cancer Patients at the Point of Care** *Small Methods*  
Inan, H., et al  
2017
  - **Monitoring Neutropenia for Cancer Patients at the Point of Care.** *Small methods*  
Inan, H., Kingsley, J. L., Ozen, M. O., Tekin, H. C., Hoerner, C. R., Imae, Y., Metzner, T. J., Preiss, J. S., Durmus, N. G., Ozsoz, M., Wakelee, H., Fan, A. C., Tüzel, et al  
2017; 1 (9)
  - **KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.** *Leukemia research*  
Swords, R. T., Greenberg, P. L., Wei, A. H., Durrant, S., Advani, A. S., Hertzberg, M. S., Lewis, I. D., Rivera, G., Gratzinger, D., Fan, A. C., Felsher, D. W., Cortes, J. E., Watts, et al  
2016; 50: 123-131
  - **Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.** *Clinical genitourinary cancer*  
Narayanan, S., Lam, A., Vaishampayan, U., Harshman, L., Fan, A., Pachynski, R., Poushnejad, S., Haas, D., Li, S., Srinivas, S.  
2016; 14 (5): 432-437
  - **Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC)**  
Meric-Bernstam, F., Tannir, N. M., Mier, J., DeMichele, A., Telli, M. L., Fan, A. C., Munster, P. N., Carvajal, R. D., Orford, K. W., Bennett, M. K., Iliopoulos, O., Owonikoko, T., Patel, et al  
AMER SOC CLINICAL ONCOLOGY.2016
  - **Prognostic factors for pancreatic metastases in renal cell cancer.**  
Chung, A., Li, S., Shah, S., Fan, A. C., Srinivas, S.  
AMER SOC CLINICAL ONCOLOGY.2016
  - **BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia** *ONCOTARGET*  
Li, Y., Deutzmann, A., Choi, P. S., Fan, A. C., Felsher, D. W.  
2016; 7 (19): 26926-26934
  - **Consolidative radiotherapy in metastatic urothelial cancer (MUC)**  
Srinivas, S., Narayanan, S., Fan, A. C., Hancock, S., Skinner, E. C.  
AMER SOC CLINICAL ONCOLOGY.2016
  - **BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia.** *Oncotarget*  
Li, Y., Deutzmann, A., Choi, P. S., Fan, A. C., Felsher, D. W.

2016

- **Phase II study of pazopanib with weekly paclitaxel in refractory urothelial cancer.**  
Srinivas, S., Narayanan, S., Harshman, L., Pachynski, R., Lam, A. P., Fan, A. C., Poushnejad, S., Haas, D., Vaishampayan, U. N.  
AMER SOC CLINICAL ONCOLOGY.2015
- **Alteration of the lipid profile in lymphomas induced by MYC overexpression.** *Proceedings of the National Academy of Sciences of the United States of America*  
Eberlin, L. S., Gabay, M., Fan, A. C., Gouw, A. M., Tibshirani, R. J., Felsher, D. W., Zare, R. N.  
2014; 111 (29): 10450-10455
- **Oncogene withdrawal engages the immune system to induce sustained cancer regression.** *Journal for immunotherapy of cancer*  
Casey, S. C., Li, Y., Fan, A. C., Felsher, D. W.  
2014; 2: 24-?
- **BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.** *Blood*  
Beurlet, S., Omidvar, N., Gorombe, P., Krief, P., Le Pogam, C., Setterblad, N., de la Grange, P., Leboeuf, C., Janin, A., Noguera, M., Hervatin, F., Sarda-Mantel, L., Konopleva, et al  
2013; 122 (16): 2864-2876
- **A c-Myc Activation Sensor-Based High-Throughput Drug Screening Identifies an Antineoplastic Effect of Nitazoxanide.** *Molecular cancer therapeutics*  
Fan-Minogue, H., Bodapati, S., Solow-Cordero, D., Fan, A., Paulmurugan, R., Massoud, T. F., Felsher, D. W., Gambhir, S. S.  
2013; 12 (9): 1896-1905
- **NANO-SCALE PROTEOMIC PROFILING TO DEFINE DIAGNOSTIC SIGNATURES AND BIOMARKERS OF THERAPEUTIC ACTIVITY IN RCC**  
Leppert, J., Fan, A., Liliental, J., Xu, L., Thong, A., Yost, C., Yaghi, A., Metzner, T., Brooks, J., Harshman, L., Sabatti, C., Srinivas, S., Felsher, et al  
ELSEVIER SCIENCE INC.2013: E246-E247
- **Nanoscale proteomic profiling to define diagnostic signatures and biomarkers of therapeutic activity in patients with RCC**  
Fan, A. C., Leppert, J., Liliental, J. E., Xu, L., Thong, A. E., Yost, C., Yaghi, A., Brooks, J. D., Harshman, L., Sabatti, C., Srinivas, S., Felsher, D. W.  
AMER SOC CLINICAL ONCOLOGY.2013
- **The Simple Western rapidly generates quantitative profiles of MAPK and PI3K proteins in clinical specimens**  
Fan, A. C., Banerjee, P., Felsher, D. W.  
AMER ASSOC CANCER RESEARCH.2012
- **Nano-scale phospho-proteomic analysis to define diagnostic signatures and biomarkers of therapeutic activity in cancer**  
Fan, A. C., Banerjee, P., Xu, L., Kong, C., Sabatti, C., Wilhelm, F., Greenberg, P., Felsher, D. W.  
AMER ASSOC CANCER RESEARCH.2012
- **Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na** *LEUKEMIA RESEARCH*  
Seetharam, M., Fan, A. C., Tran, M., Xu, L., Renschler, J. P., Felsher, D. W., Sridhar, K., Wilhelm, F., Greenberg, P. L.  
2012; 36 (1): 98-103
- **Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin's lymphoma treated with PEP-C.** *BMJ case reports*  
To, C. A., Hsieh, R. W., McClellan, J. S., Howard, W., Fischbein, N. J., Brown, J. M., Felsher, D. W., Fan, A. C.  
2012; 2012
- **"Picolog," a Synthetically-Available Bryostatins Analog, Inhibits Growth of MYC-Induced Lymphoma In Vivo** *ONCOTARGET*  
DeChristopher, B. A., Fan, A. C., Felsher, D. W., Wender, P. A.  
2012; 3 (1): 58-66
- **A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+ Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib)** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*  
Fan, A. C., Xu, L., Sridhar, K. J., Tran, M., Banerjee, P., Renschler, J. P., Tripuraneni, R., Wilhelm, F., Greenberg, P. L., Felsher, D. W.  
AMER SOC HEMATOLOGY.2011: 1626-26
- **Definition of an Enhanced Immune Cell Therapy in Mice That Can Target Stem-Like Lymphoma Cells** *CANCER RESEARCH*  
Contag, C. H., Sikorski, R., Negrin, R. S., Schmidt, T., Fan, A. C., Bachireddy, P., Felsher, D. W., Thorne, S. H.

2010; 70 (23): 9837-9845

- **Treatment of Higher Risk Myelodysplastic Syndrome Patients Unresponsive to Hypomethylating Agents with ON 01910.Na** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*  
Seetharam, M., Tran, M., Fan, A. C., Xu, L., Renschler, J. P., Felsher, D. W., Sridhar, K., Wilhelm, F., Greenberg, P. L.  
AMER SOC HEMATOLOGY.2010: 1635-35
- **ABT-737 Targets Leukemic Stem Cells In Mouse Models of Mutant NRASD12/hBCL-2-Mediated Acute Myeloid Leukemia progression with Increased Survival** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*  
Padua, R. A., Beurlet, S., Krief, P., Omidvar, N., Le Pogam, C., Auboeuf, D., de la Grange, P., Soulie, A., Janin, A., Noguera, M., Merlet, P., Sarda-Mantel, L., Fenaux, et al  
AMER SOC HEMATOLOGY.2010: 1355-56
- **CD4(+) T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation** *CANCER CELL*  
Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., Ryeom, S., Felsher, D. W.  
2010; 18 (5): 485-498
- **A rapid screening method for monitoring signaling changes in the monocyte cell line U937**  
Huang, Y., Shahjani, F., Deb-Basu, D., Fan, A., Voehringer, D., Hirschberg, D.  
AMER ASSOC CANCER RESEARCH.2009
- **Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Kampa, K. M., Acoba, J. D., Chen, D., Gay, J., Lee, H., Beemer, K., Padiernos, E., Boonmark, N., Zhu, Z., Fan, A. C., Bailey, A. S., Fleming, W. H., Corless, et al  
2009; 106 (11): 4390-4395
- **A nano-immunoassay system for monitoring changes in signaling upon oncogene inactivation in hematopoietic tumors**  
Fan, A. C., Deb-Basu, D., Gotlib, J., Voehringer, D. W., Felsher, D. W.  
AMER ASSOC CANCER RESEARCH.2007: 3610S
- **A novel nano-immunoassay system capable of absolute protein measurements from 400 tumor-derived stem cells.**  
Voehringer, D. W., Deb-Basu, D., Weissman, I., Fan, A., Nguyen, U., Bhamidipati, A., Felsher, D. W.  
AMER ASSOC CANCER RESEARCH.2007: 3556S-3556S
- **Inhibition of HMGCoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis** *BLOOD*  
Shachaf, C. M., Perez, O. D., Youssef, S., Fan, A. C., Elchuri, S., Goldstein, M. J., Shirer, A. E., Sharpe, O., Chen, J., Mitchell, D. J., Chang, M., Nolan, G. P., Steinman, et al  
2007; 110 (7): 2674-2684
- **Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Wu, C., van Riggelen, J., Yetil, A., Fan, A. C., Bachireddy, P., Felsher, D. W.  
2007; 104 (32): 13028-13033
- **Nano-fluidic detection of oncoprotein signaling in preclinical and patient lymphoma samples.**  
Fan, A. C., Deb-Basu, D., Horoschak, M., Shirer, A., Voehringer, D., O'Neill, R., Felsher, D. W.  
AMER SOC HEMATOLOGY.2006: 715A
- **ASPP2 haploinsufficiency promotes tumor formation in a mouse model.** *48th Annual Meeting of the American-Society-of-Hematology*  
Kampa, K. M., Acoba, J. D., Chen, D., Beemer, K., Gay, J., Zhu, Z., Padiernos, E., Fan, A., Felsher, D., Corless, C., Naumovski, L., Lopez, C. D.  
AMER SOC HEMATOLOGY.2006: 162B-162B
- **Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Giuriato, S., Ryeom, S., Fan, A. C., Bachireddy, P., Lynch, R. C., Rieth, M. J., van Riggelen, J., Kopelman, A. M., Passegue, E., Tang, F., Folkman, J., Felsher, D. W.  
2006; 103 (44): 16266-16271
- **MYC or RAS, but not BCL2 expression induces reversible lymphomagenesis**  
Fan, A. C., Giuriato, S., Karlsson, A., Bachireddy, P., Bendapudi, P., Rakhra, K., Padua, R., Felsher, D.



AMER ASSOC CANCER RESEARCH.2006

- **MYC quantification in lymphoma fine needle aspirates using "Firefly," a novel nanofluidic protein analysis system**  
Fan, A. C., Voehringer, D., Deb-Basu, D., Gossett, J., O'Neill, R., Felsher, D.  
AMER ASSOC CANCER RESEARCH.2006
- **Nanoliter-scale Western-blot-like BCL-2 analysis of lymphoma fine needle aspirates**  
Fan, A. C., Voehringer, D., Deb-Basu, D., Gossett, J., O'Neill, R., Felsher, D. W.  
AMER ASSOC CANCER RESEARCH.2006
- **Two oncogenic hits are required to initiate lymphomagenesis in adult, but not neonatal hosts.**  
Fan, A. C., Giuriato, S., Karlsson, A., Padua, R. A., Felsher, D. W.  
AMER SOC HEMATOLOGY.2005: 732A
- **Cooperation between MYC and BCL2 to induce lymphoma is uncovered in an adult context**  
Fan, A. C., Giuriato, S., Feng, C., Padua, R. A., Felsher, D.  
AMER SOC HEMATOLOGY.2004: 429A
- **Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer** *SEMINARS IN CANCER BIOLOGY*  
Giuriato, S., Rabin, K., Fan, A. C., Shachaf, C. M., Felsher, D. W.  
2004; 14 (1): 3-11
- **Defining the genetic contexts when MYC inactivation induces sustained regression of hematopoietic tumors.**  
Giuriato, S., Passegue, E., Fan, A., Tang, F., Felsher, D. W.  
AMER SOC HEMATOLOGY.2003: 586A
- **p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma** *CANCER*  
King, T. C., Akerley, W., Fan, A. C., Moore, T., Mangray, S., Chen, M. H., Safran, H.  
2000; 89 (4): 769-773